StockNews.com lowered shares of MiMedx Group (NASDAQ:MDXG - Free Report) from a strong-buy rating to a buy rating in a report released on Friday morning.
A number of other equities research analysts have also weighed in on MDXG. Craig Hallum lowered their target price on shares of MiMedx Group from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, August 1st. Cantor Fitzgerald reissued an "overweight" rating and issued a $11.00 price objective on shares of MiMedx Group in a research note on Thursday, August 1st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $12.00.
Get Our Latest Research Report on MiMedx Group
MiMedx Group Stock Up 1.2 %
Shares of NASDAQ:MDXG traded up $0.09 during trading on Friday, reaching $7.53. 948,727 shares of the stock were exchanged, compared to its average volume of 584,426. MiMedx Group has a 1-year low of $5.47 and a 1-year high of $9.27. The stock has a fifty day moving average of $6.11 and a two-hundred day moving average of $6.70. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of 13.69 and a beta of 1.94.
Institutional Investors Weigh In On MiMedx Group
Several large investors have recently made changes to their positions in the business. Royce & Associates LP grew its position in MiMedx Group by 5.3% during the third quarter. Royce & Associates LP now owns 972,853 shares of the company's stock valued at $5,750,000 after buying an additional 48,539 shares during the period. Victory Capital Management Inc. increased its stake in shares of MiMedx Group by 2.8% during the 3rd quarter. Victory Capital Management Inc. now owns 142,350 shares of the company's stock worth $841,000 after purchasing an additional 3,901 shares during the last quarter. Aigen Investment Management LP purchased a new position in MiMedx Group in the third quarter valued at approximately $83,000. Entropy Technologies LP purchased a new position in MiMedx Group in the third quarter valued at approximately $64,000. Finally, Principal Financial Group Inc. grew its holdings in MiMedx Group by 6.3% during the third quarter. Principal Financial Group Inc. now owns 55,495 shares of the company's stock valued at $328,000 after purchasing an additional 3,292 shares during the period. 79.15% of the stock is owned by hedge funds and other institutional investors.
MiMedx Group Company Profile
(
Get Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Featured Articles
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
